ClinicalTrials.gg
CompletedNCT02573025Updated Mar 13, 2017

A Bioequivalence Study of Pegylated Interferon Alfa-2a (PEG-IFN Alfa-2a) Benzyl Alcohol (BA)-Free Formulation Versus PEG-IFN Alfa-2a (Pegasys) Following Subcutaneous Administration

A Phase 1 interventional study of PEG-IFN alfa-2a BA-free formulation (Test) and PEG-IFN alfa-2a market formulation (Reference) in Healthy Volunteers, sponsored by Hoffmann-La Roche. Completed at 9 sites in 5 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-03-13.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
277
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is an open-label, randomized, multi-center, single dose, two-period, two-sequence crossover study to investigate the bioequivalence of PEG-IFN alfa-2a BA-free formulation versus the reference market formulation (PEG-IFN alfa-2a [Pegasys®]) following subcutaneous administration via prefilled syringe in healthy Chinese participants.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.

Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy female and male Chinese participants
  • between 19 and 28 kilograms per square meter (kg/m\^2), inclusive
  • Participants determined as healthy by their medical history, physical examination, vital signs, (ECG), and clinical laboratory measurements performed at the Screening visit
  • Female participants of : willing to use highly effective methods of throughout the study and for 90 days after the last dosing
  • Male participants: agreement to remain abstinent or use spermicide and barrier method contraception throughout the study and for 90 days after the last dosing
  • Able to participate and willing to give written and to comply with the study restrictions

Exclusion criteria

Exclusion Criteria:

  • Any condition or history of cardiovascular, psychiatric, gastrointestinal, respiratory, renal, hepatic, hematological, lymphatic, neurological (including seizure history), musculoskeletal, genitourinary, immunological, metabolic, malignant, or dermatological disorder
  • Participants who are positive for surface antigen (HBsAg), virus antibody (anti HCV) or I and II antibody (anti-HIV I, anti-HIV II) tests at Screening
  • Participants with (ALT) above the at Screening or on Day -1 of Period 1
  • Any other condition or disease (other than those already stated) which, in the judgment of the Investigator, would place the participant at undue risk, interfere with the absorption, distribution, metabolism, and excretion of PEG-IFN alfa-2a, or interfere with the ability of the participant to complete the study
  • History of drug or alcohol abuse within the last year before screening
  • Treatment with interferon or PEG-IFN alfa-2a within 3 months prior to the first dosing
  • Female participants who are pregnant, currently lactating, or have a positive serum pregnancy test at screening or have a positive urine pregnancy test on Day -1 of Period 1
  • Use of any prescribed or over the counter medication or herbal medicine taken within 14 days prior to the first dosing or within 5 times the elimination half-life of the medication prior to the first dosing (whichever is longer). Exceptions are paracetamol, the pill, hormone replacement therapy and commonly used vitamin supplements, which are permitted
  • Regular smoking with consumption of more than 10 cigarettes per day or an equivalent amount of tobacco
  • Participation in an drug or device study within 3 months prior to the first dosing
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
277 participants (actual)

Study arms

  • Experimental
    Test Followed by Reference

    Participants will receive PEG-IFN alfa-2a BA-free formulation (Test) in Period 1, followed by PEG-IFN alfa-2a market formulation (Reference) in Period 2 on Day 1 of each period with a washout period of 14 to 21 days.

    Drug: PEG-IFN alfa-2a BA-free formulation (Test) · Drug: PEG-IFN alfa-2a market formulation (Reference)

  • Experimental
    Reference Followed by Test

    Participants will receive PEG-IFN alfa-2a market formulation (Reference) in Period 1, followed by PEG-IFN alfa-2a BA-free formulation (Test) in Period 2 on Day 1 of each period with a washout period of 14 to 21 days.

    Drug: PEG-IFN alfa-2a BA-free formulation (Test) · Drug: PEG-IFN alfa-2a market formulation (Reference)

Interventions

  • DrugPEG-IFN alfa-2a BA-free formulation (Test)

    Participants will receive single injection of 180 micrograms (mcg) of PEG-IFN alfa-2a BA-free formulation, subcutaneously via prefilled syringe in either period 1 and 2 (each period having 35 days).

  • Participants will receive single injection of 180 mcg of PEG-IFN alfa-2a market formulation, subcutaneously via prefilled syringe in either period 1 and 2 (each period having 35 days).

    Also known as: Pegasys

06

What researchers measure

Primary outcomes

  1. Maximum Observed Concentration (Cmax) for PEG-IFN alfa-2a

    Time frame: Predose (-1 Hour), Hour 1, 3, 5, 8, 12, 24, 48, 72, 84, 96, 120, 144, 168, 192, 216, 240, 312, 384, 480, 552, 648, 816 post Dose

  2. Area Under the Concentration-Time Curve (AUC) for PEG-IFN alfa-2a From Time Zero to 816 hours (AUC0-816h)

    Time frame: Predose (-1 Hour), Hour 1, 3, 5, 8, 12, 24, 48, 72, 84, 96, 120, 144, 168, 192, 216, 240, 312, 384, 480, 552, 648, 816 post Dose

Secondary outcomes

  1. Area Under the Concentration-Time Curve for PEG-IFN alfa-2a From Time Zero Extrapolated to Infinity (AUC0-inf)

    Time frame: Predose (-1 Hour), Hour 1, 3, 5, 8, 12, 24, 48, 72, 84, 96, 120, 144, 168, 192, 216, 240, 312, 384, 480, 552, 648, 816 post Dose

  2. Time to Reach Cmax (tmax) for PEG-IFN alfa-2a

    Time frame: Predose (-1 Hour), Hour 1, 3, 5, 8, 12, 24, 48, 72, 84, 96, 120, 144, 168, 192, 216, 240, 312, 384, 480, 552, 648, 816 post Dose

  3. Terminal Half-Life (t1/2) for PEG-IFN alfa-2a

    Time frame: Predose (-1 Hour), Hour 1, 3, 5, 8, 12, 24, 48, 72, 84, 96, 120, 144, 168, 192, 216, 240, 312, 384, 480, 552, 648, 816 post Dose

  4. Percentage of Participants With Adverse Events

    Time frame: Baseline up to 35 days post last dose of PEG-IFN alfa-2a (maximum up to 17.5 weeks)

07

Study locations

9 sites
  • CMAX A division of IDT Australia Limited
    Adelaide, South Australia 5000, Australia
  • The University of Hong Kong; Pharmacy Clinical Trials
    Hong Kong, Hong Kong
  • The Chinese University of Hong Kong; Emergency Medicine
    Shatin, 00000, Hong Kong
  • Christchurch Clinical Studies Trust
    Christchurch, 8011, New Zealand
  • Auckland Clinical Studies Limited
    Grafton, 1010, New Zealand
  • SingHealth Investigational Medicine Unit; Haematology
    Singapore, 169608, Singapore
  • Changi General Hospital- Parent; Department of Rheumatology
    Singapore, 529889, Singapore
  • China Medical University Hospital;Oncology and Hematology Office Critical Care Center, 14H
    Taichung, 404, Taiwan
  • Taipei Medical University Hospital; Clinical Research Center
    Taipei City, 110, Taiwan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2015 to primary completion in Apr 2016, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2015
First posted
Oct 9, 2015
StartActual
Sep 17, 2015
Primary completionActual
Apr 11, 2016
CompletionActual
Apr 11, 2016
Last update
Mar 13, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02573025
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Oct 9, 2015
Start date
Sep 17, 2015
Primary completion
Apr 11, 2016
Completion
Apr 11, 2016
Last update
Mar 13, 2017

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Peginterferon alfa-2a

Start the discussion